Therapeutic Asset Ratings

123 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
VINCRISTINE SULFATE Leukemia	Inhye Ahn	P3	BB (71)
Cyclophosphamide Leukemia	National Cancer Institute (NCI)	P4	BB (70)
FILGRASTIM Leukemia	Hospital General de Mexico	P4	BB (70)
Daunorubicin Leukemia	Richard Stone, MD	P3	BB (70)
Idarubicine Leukemia	Affiliated Hospital of Nantong University	P3	BB (70)
MERCAPTOPURINE ANHYDROUS Leukemia	Dana-Farber Cancer Institute	P3	BB (70)
PEGASPARGASE Leukemia	Dana-Farber Cancer Institute	P3	BB (70)
Busulphan Leukemia	National Cancer Institute (NCI)	P4	BB (69)
ETOPOSIDE Leukemia	Memorial Sloan Kettering Cancer Center	P3	BB (69)
Inno-206 Leukemia	Dana-Farber Cancer Institute	P3	BB (69)
PREDNISONE TABLETS Leukemia	Inhye Ahn	P3	BB (69)
Cytosin-Arabinosid Leukemia	Dana-Farber Cancer Institute	P3	BB (68)
DEXAMETHASONE Leukemia	Dana-Farber Cancer Institute	P3	BB (68)
METHOTREXATE Leukemia	Dana-Farber Cancer Institute	P3	BB (68)
Mitoxantrone Leukemia	University of Colorado, Denver	P3	BB (68)
CYCLOSPORIN A Leukemia	Memorial Sloan Kettering Cancer Center	P4	BB (67)
Fludarabine Leukemia	National Cancer Institute (NCI)	P3	BB (67)
Ifosfamide Leukemia	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	P3	BB (67)
Romidepsin Leukemia	National Cancer Institute (NCI)	P3	BB (67)
(+)-VINCRISTINE Leukemia	Dana-Farber Cancer Institute	P2/3	BB (67)
Anti-Thymoglobulin, Rabbit Leukemia	Peking University First Hospital	P4	BB (66)
Thiotepa Leukemia	Memorial Sloan Kettering Cancer Center	P4	BB (66)
Evomela Leukemia	Shanghai Jiao Tong University School of Medicine	P3	BB (66)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Leukemia	University of Chicago	P3	BB (66)
Vesanoid Leukemia	SDK Therapeutics, Inc.	P3	BB (66)

Showing 1 to 25 of 123 assets

PreviousPage 1 of 5Next